Core Insights - OraSure Technologies, Inc. reported a total revenue of $27.1 million for Q3 2025, a decrease of 32% compared to $39.9 million in Q3 2024 [10] - The company anticipates a return to growth in 2026, driven by diversification in its customer base and new product launches [2][3] Financial Performance - Core business revenues decreased by 25% year-over-year to $27.0 million, while COVID-19 related revenues fell by 96% to $89,000 [4][10] - Gross profit for Q3 2025 was $11.8 million, down 31% from $17.1 million in Q3 2024, with a gross margin of 43.5% [5][10] - The operating loss for Q3 2025 was $16.1 million, compared to a loss of $6.0 million in Q3 2024 [5][10] Product and Service Revenue Breakdown - Diagnostics revenues decreased by 34% year-over-year to $14.5 million, primarily due to lower revenue from HIV tests [10] - Sample Management Solutions revenues fell by 20% year-over-year to $10.3 million, attributed to a large customer in the consumer genomics segment [10] - Total net revenues for the nine months ended September 30, 2025, were $88.3 million, down 41% from $148.4 million in the same period of 2024 [4][10] Strategic Developments - The company signed a definitive agreement to acquire BioMedomics, which will enhance its diagnostic portfolio with SickleSCAN, a rapid test for sickle cell disease [11] - OraSure extended its collaboration with the Together Take Me Home program to provide HIV self-tests to at-risk populations [11] - The company appointed Steven K. Boyd to its Board of Directors, bringing valuable experience in public markets and healthcare [11] Financial Guidance - For Q4 2025, the company projects total revenues between $25 million and $28 million, with less than $100,000 expected from COVID-19 testing [8]